Fear extinction learning as a predictor of response to cognitive behavioral therapy for pediatric obsessive compulsive disorder.


Journal

Journal of anxiety disorders
ISSN: 1873-7897
Titre abrégé: J Anxiety Disord
Pays: Netherlands
ID NLM: 8710131

Informations de publication

Date de publication:
05 2019
Historique:
received: 22 06 2018
revised: 22 01 2019
accepted: 26 02 2019
pubmed: 11 3 2019
medline: 31 3 2020
entrez: 11 3 2019
Statut: ppublish

Résumé

While cognitive behavior therapy (CBT) is an effective treatment for many children and adolescents with Obsessive Compulsive Disorder (OCD), therapeutic response is variable. Fear conditioning and extinction are central constructs underlying exposure-based CBT. Fear extinction learning assessed prior to CBT may be a useful predictor of CBT response for guiding treatment decisions. Sixty-four youth who participated in a randomized placebo-controlled trial of CBT with and without d-cycloserine (DCS) completed a fear conditioning task. Skin conductance response (SCR) scores were used to measure fear acquisition and extinction to determine whether extinction learning could predict CBT response. CBT responders and non-responders appeared to acquire conditioned fear SCRs in a similar manner. However, differences between treatment responders and non-responders emerged during the extinction phase. A responder (responder, non-responder) by conditioned stimulus type (CS+, CS-) interaction showed that CBT responders differentiated the stimulus paired with (CS+) and without (CS-) the unconditioned stimulus correctly during early and late extinction, whereas the CBT non-responders did not (p = .004). While the small sample size makes conclusions tentative, this study supports an emerging literature that differential fear extinction may be an important factor underlying clinical correlates of pediatric OCD, including CBT response.

Sections du résumé

BACKGROUND
While cognitive behavior therapy (CBT) is an effective treatment for many children and adolescents with Obsessive Compulsive Disorder (OCD), therapeutic response is variable. Fear conditioning and extinction are central constructs underlying exposure-based CBT. Fear extinction learning assessed prior to CBT may be a useful predictor of CBT response for guiding treatment decisions.
METHODS
Sixty-four youth who participated in a randomized placebo-controlled trial of CBT with and without d-cycloserine (DCS) completed a fear conditioning task. Skin conductance response (SCR) scores were used to measure fear acquisition and extinction to determine whether extinction learning could predict CBT response.
RESULTS
CBT responders and non-responders appeared to acquire conditioned fear SCRs in a similar manner. However, differences between treatment responders and non-responders emerged during the extinction phase. A responder (responder, non-responder) by conditioned stimulus type (CS+, CS-) interaction showed that CBT responders differentiated the stimulus paired with (CS+) and without (CS-) the unconditioned stimulus correctly during early and late extinction, whereas the CBT non-responders did not (p = .004).
CONCLUSIONS
While the small sample size makes conclusions tentative, this study supports an emerging literature that differential fear extinction may be an important factor underlying clinical correlates of pediatric OCD, including CBT response.

Identifiants

pubmed: 30852257
pii: S0887-6185(18)30253-6
doi: 10.1016/j.janxdis.2019.02.005
pmc: PMC7422704
mid: NIHMS1612173
pii:
doi:

Substances chimiques

Cycloserine 95IK5KI84Z

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH093381
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH093402
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Lancet. 2009 Aug 8;374(9688):491-9
pubmed: 19665647
Ann Clin Psychiatry. 2017 Feb;29(1):17-26
pubmed: 28207912
Depress Anxiety. 2016 Mar;33(3):229-37
pubmed: 26799264
Arch Gen Psychiatry. 1989 Apr;46(4):335-41
pubmed: 2930330
JAMA Psychiatry. 2014 Jun;71(6):689-98
pubmed: 24759852
J Clin Child Adolesc Psychol. 2007 Oct-Dec;36(4):645-53
pubmed: 18088221
J Am Acad Child Adolesc Psychiatry. 2017 Nov;56(11):940-947.e1
pubmed: 29096776
Arch Gen Psychiatry. 1993 Jun;50(6):429-39
pubmed: 8498877
J Am Acad Child Adolesc Psychiatry. 2007 Apr;46(4):469-478
pubmed: 17420681
J Abnorm Psychol. 2009 May;118(2):311-21
pubmed: 19413406
Psychol Bull. 1955 Jul;52(4):281-302
pubmed: 13245896
Depress Anxiety. 2013 Sep;30(9):822-8
pubmed: 23658147
J Am Acad Child Adolesc Psychiatry. 1995 Nov;34(11):1424-31
pubmed: 8543509
J Abnorm Child Psychol. 2015 Apr;43(3):543-52
pubmed: 25052626
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Behav Res Ther. 2006 Oct;44(10):1491-502
pubmed: 16360117
Neuropsychopharmacology. 2014 Mar;39(4):875-84
pubmed: 24126454
Am J Psychiatry. 2013 Oct;170(10):1195-204
pubmed: 23929092
J Am Acad Child Adolesc Psychiatry. 2014 Jan;53(1):61-71
pubmed: 24342386
Child Adolesc Psychiatr Clin N Am. 1999 Jul;8(3):445-60
pubmed: 10442225
Behav Res Ther. 2005 Nov;43(11):1391-424
pubmed: 15885654
J Child Psychol Psychiatry. 2016 Jul;57(7):869-76
pubmed: 26871483
J Anxiety Disord. 2014 Mar;28(2):125-32
pubmed: 23774008
Cogn Emot. 2013;27(5):914-22
pubmed: 23216275
Mol Psychiatry. 2007 Feb;12(2):120-50
pubmed: 17160066
J Abnorm Child Psychol. 1993 Aug;21(4):411-23
pubmed: 8408987
J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):94-102
pubmed: 18174830
J Abnorm Psychol. 2000 May;109(2):290-8
pubmed: 10895567
Biol Psychol. 2014 Jul;100:1-12
pubmed: 24746848
J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1024-33; quiz 1086
pubmed: 20855047
J Am Acad Child Adolesc Psychiatry. 2008 May;47(5):583-592
pubmed: 18356759
JAMA. 2004 Oct 27;292(16):1969-76
pubmed: 15507582
Dev Psychobiol. 2012 Nov;54(7):675-84
pubmed: 22072276
Behav Res Ther. 2014 Jul;58:10-23
pubmed: 24864005
Behav Res Ther. 2008 Aug;46(8):954-67
pubmed: 18539262
Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4500-5
pubmed: 21368210
JAMA Psychiatry. 2016 Aug 1;73(8):779-88
pubmed: 27367832
Depress Anxiety. 2015 Aug;32(8):580-93
pubmed: 26130211
Cogn Behav Pract. 2019 Feb;26(1):214-224
pubmed: 31205406
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16318-23
pubmed: 22988092
Depress Anxiety. 2015 Apr;32(4):277-88
pubmed: 25427438

Auteurs

Daniel A Geller (DA)

Massachusetts General Hospital, 185 Cambridge Street, Suite 2000, Boston, MA, 02114, United States; Harvard University Medical School, Boston, MA, United States. Electronic address: dan.geller@mgh.harvard.edu.

Joseph F McGuire (JF)

Division of Child and Adolescent Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: jfmcguire@jhmi.edu.

Scott P Orr (SP)

Massachusetts General Hospital, 185 Cambridge Street, Suite 2000, Boston, MA, 02114, United States; Harvard University Medical School, Boston, MA, United States. Electronic address: scott_orr@hms.harvard.edu.

Brent J Small (BJ)

School of Aging Studies, University of South Florida, 13301 Bruce B Downs Blvd, Tampa, FL, 33620, United States. Electronic address: bsmall@usf.edu.

Tanya K Murphy (TK)

Department of Pediatrics, University of South Florida, Rothman Center for Neuropsychiatry, United States; Department of Psychiatry & Behavioral Neurosciences, University of South Florida, United States.

Kathleen Trainor (K)

Massachusetts General Hospital, 185 Cambridge Street, Suite 2000, Boston, MA, 02114, United States. Electronic address: kbtrainor@mgh.harvard.edu.

Rachel Porth (R)

Massachusetts General Hospital, 185 Cambridge Street, Suite 2000, Boston, MA, 02114, United States. Electronic address: rporth@mgh.harvard.edu.

Sabine Wilhelm (S)

Massachusetts General Hospital, 185 Cambridge Street, Suite 2000, Boston, MA, 02114, United States; Harvard University Medical School, Boston, MA, United States. Electronic address: swilhelm@mgh.harvard.edu.

Eric A Storch (EA)

Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd, Suite 400, Houston 77030, TX, United States. Electronic address: Eric.Storch@bcm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH